CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 500 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Senexin C
CAS:<p>Senexin C is a CDK8/19 inhibitor with anticancer activity.Senexin C inhibits the growth of MV4-11 leukemia cells.</p>Fórmula:C28H27N5OPureza:98.06%Cor e Forma:SolidPeso molecular:449.55Bisindolylmaleimide X hydrochloride
CAS:<p>Bisindolylmaleimide X hydrochloride (BIM-X hydrochloride) is a potent and selective PKC inhibitor. It is also a potent CDK2 antagonist (IC50: 200 nM).</p>Fórmula:C26H25ClN4O2Pureza:99.23%Cor e Forma:SolidPeso molecular:460.96Cdc7-IN-7
CAS:<p>Cdc7-IN-7 is a potent inhibitor of Cdc7 kinase.</p>Fórmula:C21H22N4O5Pureza:98.78%Cor e Forma:SolidPeso molecular:410.42CDK9-IN-23
CAS:<p>CDK9-IN-23 (Example 4) is a potent inhibitor of CDK9, exhibiting an IC50 value of less than 20 nM [1].</p>Fórmula:C22H25ClN4O3Pureza:98%Cor e Forma:SolidPeso molecular:428.91Senexin A hydrochloride
CAS:<p>Senexin A hydrochloride functions as a selective inhibitor of CDK8/19, with an IC 50 of 280 nM for CDK8, and specifically inhibits p21-induced transcription without affecting other biological effects of p21. Additionally, it suppresses CMV-GFP induction and the stimulatory activity of the consensus NF-κB-dependent promoters [1] [2].</p>Fórmula:C17H15ClN4Cor e Forma:SolidPeso molecular:310.78CDK9-IN-19
CAS:<p>CDK9-IN-19: Potent CDK9 inhibitor, anti-cancer, moderate pharmacokinetics, low hERG impact, effective in AML research.</p>Fórmula:C26H22F2N4O5Cor e Forma:SolidPeso molecular:508.47Riviciclib
CAS:<p>Riviciclib, a CDK inhibitor (CDK9/T1, CDK4/D1, CDK1/B), has IC50s: 20, 63, 79 nM respectively, and fights cisplatin-resistant tumors.</p>Fórmula:C21H20ClNO5Pureza:98%Cor e Forma:SolidPeso molecular:401.84ML 315 hydrochloride
CAS:<p>ML 315, a selective dual inhibitor targeting CDK (Cyclin-Dependent Kinase) and DYRK (Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase) with IC50 values of 68 nM and 282 nM, respectively, is utilized in research pertaining to cancer and neurological diseases [1].</p>Fórmula:C18H14Cl3N3O2Cor e Forma:SolidPeso molecular:410.682(S)-Cdc7-IN-18
CAS:<p>'(S)-Cdc7-IN-18 from patent WO2020239107A1 inhibits CDC7, curbing MCM2 and tumor growth.'</p>Fórmula:C19H21N5OSCor e Forma:SolidPeso molecular:367.47CDK7-IN-25
CAS:<p>CDK7-IN-25 (CY-16-1) is a potent CDK7 inhibitor with an IC50 value of less than 1nM, utilized in cancer research [1].</p>Fórmula:C33H32N6O3Pureza:98%Cor e Forma:SolidPeso molecular:560.65Inixaciclib
CAS:<p>Inixaciclib is a potent CDK inhibitor, can be used to research anticancer.</p>Fórmula:C26H30F2N6OCor e Forma:SolidPeso molecular:480.55SZ-015268
CAS:<p>SZ-015268: CDK7 inhibitor, IC50=23.56 nM; hinders HCC70, OVCAR-3, HCT116, HCC1806 cell growth; strong anti-tumor effect.</p>Fórmula:C25H38N8O3Cor e Forma:SolidPeso molecular:498.62CDK4/6-IN-15
CAS:<p>CDK4/6-IN-15: Oral, selective CDK4/6 inhibitor, halts cancer cell growth, G1 arrest, suppresses Rb phosphorylation.</p>Fórmula:C21H27FN8SCor e Forma:SolidPeso molecular:442.56CDK4/6-IN-17
CAS:<p>CDK4/6-IN-17 (compound 12) is an orally bioavailable inhibitor of CDK4/6, demonstrating potent activity with IC50 values between 10-100 nM in BE(2) cells.</p>Fórmula:C27H28F4N8Pureza:98%Cor e Forma:SolidPeso molecular:540.56Cdc7-IN-12
CAS:<p>Cdc7-IN-12, a sub-1 nM CDC7 inhibitor, may aid cancer research; hinders COLO205 cell growth (IC50: 100-1000 nM).</p>Fórmula:C16H14N2O2SCor e Forma:SolidPeso molecular:298.36Xylocydine
CAS:<p>Xylocydine is a novel Cdk inhibitor that induces apoptosis in HCC, suppresses tumor growth, and is non-toxic to other tissues.</p>Fórmula:C12H14BrN5O5Cor e Forma:SolidPeso molecular:388.17CF53
CAS:<p>CF53: potent, selective oral BET inhibitor; Ki <1 nM, Kd 2.2 nM, IC50 2 nM for BRD4 BD1; high affinity for BRD2/3/4/BRDT; effective anti-tumor agent.</p>Fórmula:C24H25N7O2Pureza:99.72%Cor e Forma:SolidPeso molecular:443.5Cdk1/2 Inhibitor III
CAS:<p>Cdk1/2 Inhibitor III is a selective Cdk1/2 inhibitor with an IC50 value of 2.1 μM against CDK1/cyclin B.</p>Fórmula:C15H13F2N7O2S2Pureza:99.07%Cor e Forma:SolidPeso molecular:425.44(R)-Simurosertib
CAS:<p>(R)-Simurosertib ((R)-TAK-931) is an inhibitor of the ATP-competitive cell division cycle 7 (CDC7) kinase.</p>Fórmula:C17H19N5OSPureza:99.89%Cor e Forma:SolidPeso molecular:341.43XY028-140
CAS:<p>XY028-140 is a selective CDK4/6 inhibitor and degrader, acting via PROTAC with ligands for Cereblon and CDK in cancer cells.</p>Fórmula:C39H40N10O7Pureza:98.59%Cor e Forma:SolidPeso molecular:760.8Debio-0123
CAS:Debio-0123: potent, specific oral WEE1 inhibitor; IC50 in low nanomolar; boosts DNA damage & Carboplatin's anti-cancer effects.Fórmula:C26H28Cl2N6OPureza:99.93%Cor e Forma:SolidPeso molecular:511.45AZD4573
CAS:<p>AZD4573 is an effective and selective CDK9 inhibitor (IC50: <4 nM). It enables transient target engagement for the treatment of hematologic malignancies.</p>Fórmula:C22H28ClN5O2Pureza:99% - 99.51%Cor e Forma:SolidPeso molecular:429.94PPA-037
CAS:<p>PPA-037 is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). It induces the degradation of Cyclin K, thereby enhancing antiproliferative effects on tumor cells. PPA-037 holds potential for use in cancer research.</p>Fórmula:C25H27N7Cor e Forma:SolidPeso molecular:425.53CDK1-IN-7
CAS:<p>CDK1-IN-7 (compound M7) is a potent CDK1 inhibitor. It effectively suppresses the proliferation and migration of HCT116 and Lovo cells, making it a valuable tool for colorectal cancer research.</p>Fórmula:C23H19ClN4O3Cor e Forma:SolidPeso molecular:434.88YL-1-9
CAS:<p>YL-1-9 is an inhibitor that prevents the degradation of p53 by MDM2 through tight binding to the crucial hydrophobic pocket of MDM2. It can induce cell cycle arrest and apoptosis in breast cancer cells [1].</p>Fórmula:C22H23F3N2O3Cor e Forma:SolidPeso molecular:420.425CDK9 autophagic degrader 1
CAS:<p>CDK9 autophagic degrader 1 (Compound 28) is an ATTEC degrader used to target and degrade CDK9, also impacting the levels of its associated Cyclin T1. At a concentration of 100 nM, it exhibits over 80% inhibition of CDK9.</p>Fórmula:C34H39N7O4S2Cor e Forma:SolidPeso molecular:673.848CDK9-IN-11
CAS:<p>CDK9-IN-11 is a potent CDK9 inhibitor that is the ligand for the PROTAC CDK9 Degrader-1 [1].</p>Fórmula:C20H25N3O4Pureza:98%Cor e Forma:SolidPeso molecular:371.43RGB-286638
CAS:<p>RGB-286638 inhibits multiple CDKs and GSK-3β, TAK1, Jak2, MEK1 with IC50s as low as 1-54 nM.</p>Fórmula:C29H37Cl2N7O4Cor e Forma:SolidPeso molecular:618.55Cimpuciclib tosylate
CAS:<p>Cimpuciclib tosylate, a selective CDK4 inhibitor (IC50: 0.49 nM), exhibits anti-tumor activity.</p>Fórmula:C37H43FN8O4SCor e Forma:SolidPeso molecular:714.85CDK2/4-IN-2
CAS:<p>CDK2/4-IN-2 (compound 56) serves as a dual inhibitor for CDK2 and CDK4, exhibiting an IC50 of less than 100 nM. It is applicable in cancer research.</p>Fórmula:C18H20F3N7O3S2Cor e Forma:SolidPeso molecular:503.52CDK2 degrader 4
CAS:<p>CDK2 degrader4 (compound 104) is a potent degrader of CDK2, showing promise for cancer research applications.</p>Fórmula:C23H26ClN3O5Cor e Forma:SolidPeso molecular:459.923CDK8-IN-9
<p>CDK8-IN-9, potent CDK8 inhibitor (IC50: 48.6 nM), curbs tumor growth, useful for colorectal cancer research.</p>Cor e Forma:SolidPROTAC CDK12/13 Degrader-1
<p>PROTAC CDK12/13 Degrader-1 (7f) selectively degrades CDK12/13 at nanomolar potency, targeting breast cancer.</p>Cor e Forma:SolidCDK7-IN-33
CAS:<p>CDK7-IN-33 (Compound 148) is a CDK7 inhibitor with a Ki value of 21.75 nM. It suppresses the proliferation of A549 cells expressing CDK7WT, with a pIC50 of 7.37.</p>Fórmula:C29H36N6O4SCor e Forma:SolidPeso molecular:564.699CDK/HDAC-IN-1
<p>CDK/HDAC-IN-1 inhibits CDK2/4/6 & HDAC6 with IC50s: 60.9, 276, 27.2, and 128.6 nM respectively.</p>Fórmula:C20H18N4O4Cor e Forma:SolidPeso molecular:378.38LZ9
CAS:<p>LZ9 is an ATP-competitive inhibitor of CDK1 and CDK2, with potential applications in colorectal cancer (CRC) research.</p>Fórmula:C17H11F3N4O2Cor e Forma:SolidPeso molecular:360.29CDK1-IN-3
<p>CDK1-IN-3 is a selective inhibitor targeting CDK1 (36.8 nM), CDK2 (305.17 nM), CDK5 (369.37 nM); used in cancer research.</p>Fórmula:C28H25ClF3N5O2Cor e Forma:SolidPeso molecular:555.98Haspin-IN-2
CAS:<p>Haspin-IN-2 is a potent haspin inhibitor (IC50: 50 nM) and also inhibits CLK1 (IC50: 445 nM) and DYRK1A (IC50: 917 nM).</p>Fórmula:C12H8N4O3Cor e Forma:SolidPeso molecular:256.22CDK4-IN-1
CAS:<p>CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50</p>Fórmula:C22H29ClN8Pureza:98%Cor e Forma:SolidPeso molecular:440.97Cdc7-IN-10
CAS:<p>Cdc7-IN-10 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in studies of proliferative diseases.</p>Fórmula:C20H22F2N4O2SCor e Forma:SolidPeso molecular:420.48DDO-6079
CAS:<p>DDO-6079 is an efficient CDC37 inhibitor. It suppresses the HSP90-CDC37 and CDC37-CDK4/6 chaperone complexes by binding to an allosteric site on CDC37. Additionally, DDO-6079 reduces the thermal stability of CDK6.</p>Fórmula:C18H13ClN2O3Cor e Forma:SolidPeso molecular:340.76CDK7-IN-18
CAS:<p>CDK7-IN-18: potent, pyrimidine-based CDK7 inhibitor with cancer research potential.</p>Fórmula:C22H24F3N7OSCor e Forma:SolidPeso molecular:491.53CLK1/2-IN-1
CAS:<p>CLK1/2-IN-1 is a CLK1 and CLK2 inhibitor and it also inhibits SRPK1 and SRPK2.</p>Fórmula:C21H20F3N7OPureza:98%Cor e Forma:SolidPeso molecular:443.42TMX-3013
CAS:<p>TMX-3013 is a CDK inhibitor that targets multiple cyclin-dependent kinases, specifically suppressing the activity of CDK1, CDK2, CDK4, CDK5, and CDK6 with IC50 values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM respectively. Additionally, TMX-3013 is utilized in the synthesis of PROTACs, which use polyethylene glycol (PEG) as a linker and Thalidomide as the CRBN-recruiting arm.</p>Fórmula:C17H14BrFN6O3SCor e Forma:SolidPeso molecular:481.3CDK2-IN-8
<p>CDK2-IN-8 is a potent CDK2 inhibitor (IC50= 1.74 μM). CDK2-IN-8 exhibits antiproliferative activity. CDK2-IN-8 can be used for the research of melanoma.</p>Fórmula:C22H25N5O3Cor e Forma:SolidPeso molecular:407.47CDK2-IN-31
CAS:<p>CDK2-IN-31 (compound I-125A) is an inhibitor of CDK2 and is utilized in cancer research.</p>Fórmula:C37H52N6O5Cor e Forma:SolidPeso molecular:660.85CDK12/13 ligand 1
CAS:<p>ALK-IN-29 (compound 4c) exhibits notable inhibitory activity against tyrosine kinases such as ALK, CDK2/CyclinE1, and FAK, with the strongest inhibition observed against ALK kinase, showing a 40.63% inhibition rate at a concentration of 10 μM. ALK-IN-29 is useful for cancer research.</p>Fórmula:C26H26BrN5OCor e Forma:SolidPeso molecular:504.42CDK1-IN-5
<p>CDK1-IN-5 is a selective inhibitor for CDK1 (IC50: 42.19 nM), CDK2, CDK5, halting cancer cell growth.</p>Fórmula:C27H26ClN5OSCor e Forma:SolidPeso molecular:504.05CDK5-IN-2
CAS:<p>CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor that acts on CDK5/p25 (IC50: 0.2 nM) and CDK2/CycA (IC50: 23 nM).</p>Fórmula:C29H28FN5OCor e Forma:SolidPeso molecular:481.56CDK8-IN-14
CAS:<p>CDK8-IN-14 (compound 12) effectively inhibits CDK8, demonstrating an IC50 of 39.2 nM, and exhibits potent anti-AML cell proliferation effects, with a GC50 value of 0.02±0.01μM in MOLM-13 cells and 0.03±0.01μM in MV4-11 cells [1].</p>Fórmula:C18H13N3O2Cor e Forma:SolidPeso molecular:303.31
